IN BRIEF: J&J submits application for Tremfya approval in the US

21st June 2024 19:19

Johnson & Johnson - New Brunswick, New Jersey-based pharmaceutical company - Submits application to US Food & Drug Administration for approval of its Tremfya monoclonal antibody in adults with moderately to severely active Crohn's disease. Follows positive results from its Graviti, Galaxi 2 and Galaxi 3 trials. In March it submitted an application to the FDA for Tremfya approval for moderately to severely active ulcerative colitis. Tremfya interacts with the IL-23 protein, whose dysregulation can play a role in autoimmune disease.

David Lee at J&J Innovative Medicine says: "Building upon nearly three decades of leadership and innovation in immunology, we are committed to addressing the needs of people living with Crohn’s disease through deep, scientific expertise and through our continued pioneering advances in the IL-23 pathway."

Current share price: USD148.87, up 0.7% in New York on Monday afternoon

12-month change: down 9.2%

By Aidan Lane, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Get more news and expert articles direct to your inbox